NCT07767175RecruitingPhase 1
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- First submitted
- 11 Aug 2026
- Start date
- 12 Aug 2026
- Primary completion date
- 23 Sept 2027
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07767175
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 142
- From 12 Aug 2026 to the primary completion date, 23 Sept 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous randomisation in this study.
Other illness
- Known or suspected hypersensitivity to study intervention(s) or related products.
- History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
- Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
Lab values
- Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.
Other
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
- Current participation (signed informed consent) in any other interventional clinical study.
- Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
Who the study is looking for
- Male or female (sex at birth).
- Age 18-55 years (both inclusive) at the time of signing informed consent.
- Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
- Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ICON Early Phase Services, LLC Coordinator of this site? Confirm its status | Lenexa | United States | Recruiting |
| ICON Coordinator of this site? Confirm its status | San Antonio | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.